IBD in the COVID-19 era: the value of international collaboration

Erica J. Brenner; Ryan C. Ungaro; Jean Frederic Colombel; Michael D. Kappelman

doi:10.1016/S2468-1253(20)30269-7

IBD in the COVID-19 era: the value of international collaboration

Erica J. Brenner, Ryan C. Ungaro, Jean Frederic Colombel, Michael D. Kappelman

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English
Pages (from-to)	887-888
Number of pages	2
Journal	The Lancet Gastroenterology and Hepatology
Volume	5
Issue number	10
DOIs	https://doi.org/10.1016/S2468-1253(20)30269-7
State	Published - Oct 2020

Access to Document

10.1016/S2468-1253(20)30269-7

Cite this

@article{fb29326778ed448cb178ffa093af7128,

title = "IBD in the COVID-19 era: the value of international collaboration",

author = "Brenner, {Erica J.} and Ungaro, {Ryan C.} and Colombel, {Jean Frederic} and Kappelman, {Michael D.}",

note = "Funding Information: EJB and RCU contributed equally to this Correspondence. SECURE-IBD was funded by the Helmsley Charitable Trust (2003-04445), CTSA grant number UL1TR002489, T32DK007634 (EJB), and K23KD111995-01A1 (RCU). Additional funding was provided by Pfizer, Takeda, Janssen, AbbVie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, and Arena Pharmaceuticals. RCU is supported by an NIH K23 Career Development Award (K23KD111995-01A1); has served as an advisory board member or consultant for Eli Lilly, Janssen, Pfizer, and Takeda; and has received research support from AbbVie, Boehringer Ingelheim, and Pfizer. J-FC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; and holds stock options in Intestinal Biotech Development and Genfit. MDK has consulted for AbbVie, Janssen, and Takeda; is a shareholder in Johnson & Johnson; and has received research support from AbbVie and Janssen. EJB declares no competing interests.",

year = "2020",

month = oct,

doi = "10.1016/S2468-1253(20)30269-7",

language = "English",

volume = "5",

pages = "887--888",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd.",

number = "10",

}

TY - JOUR

T1 - IBD in the COVID-19 era

T2 - the value of international collaboration

AU - Brenner, Erica J.

AU - Ungaro, Ryan C.

AU - Colombel, Jean Frederic

AU - Kappelman, Michael D.

N1 - Funding Information: EJB and RCU contributed equally to this Correspondence. SECURE-IBD was funded by the Helmsley Charitable Trust (2003-04445), CTSA grant number UL1TR002489, T32DK007634 (EJB), and K23KD111995-01A1 (RCU). Additional funding was provided by Pfizer, Takeda, Janssen, AbbVie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, and Arena Pharmaceuticals. RCU is supported by an NIH K23 Career Development Award (K23KD111995-01A1); has served as an advisory board member or consultant for Eli Lilly, Janssen, Pfizer, and Takeda; and has received research support from AbbVie, Boehringer Ingelheim, and Pfizer. J-FC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; and holds stock options in Intestinal Biotech Development and Genfit. MDK has consulted for AbbVie, Janssen, and Takeda; is a shareholder in Johnson & Johnson; and has received research support from AbbVie and Janssen. EJB declares no competing interests.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85090577846&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(20)30269-7

DO - 10.1016/S2468-1253(20)30269-7

M3 - Letter

C2 - 32941833

AN - SCOPUS:85090577846

SN - 2468-1253

VL - 5

SP - 887

EP - 888

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 10

ER -